# OnCo record anlotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/anlotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "anlotinib" ;
  schema:name "Anlotinib"@en ;
  schema:alternateName "Catequentinib"@en, "Qezzaqar"@en, "Focus V" ;
  schema:description "Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours."@en ;
  schema:url <https://onco.cc/drugs/anlotinib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anlotinib> ;
  schema:citation <https://web.archive.org/web/20251122085435/https://www.sinobiopharm.com/en/>, <https://doi.org/10.1001/jamaoncol.2018.3039>, <https://www.nmpa.gov.cn> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)" ;
  onco:approval "China 2018: Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)", "China 2019: Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines", "China 2020: Advanced medullary thyroid cancer" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/alveolar-soft-part-sarcoma/>, <https://onco.cc/cancers/thyroid/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/fgfr2/>, <https://onco.cc/targets/kit/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:trials <https://onco.cc/trials/alter-0303/>, <https://onco.cc/trials/nct04854668/>, <https://onco.cc/trials/nct05862337/>, <https://onco.cc/trials/nct03016819/>, <https://onco.cc/trials/nct05913089/>, <https://onco.cc/trials/nct07548177/>, <https://onco.cc/trials/nct07562581/> .